Leflunomide

BNF:: 10.1.3
Status:: Amber
Decision Date:: None

Comments

See shared care guideline for immunomodulating drugs

Amber Drug Classifications

1: Requiring specialist assessment to enable patient selection and initiation of treatment
2: Requiring short or medium term (e.g. 3-6 months) specialist monitoring of efficacy or until the patient is stable